GPR56/ADGRG1 is associated with response to antidepressant treatment.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
02 04 2020
Historique:
received: 05 02 2019
accepted: 10 03 2020
entrez: 4 4 2020
pubmed: 4 4 2020
medline: 25 7 2020
Statut: epublish

Résumé

It remains unclear why many patients with depression do not respond to antidepressant treatment. In three cohorts of individuals with depression and treated with serotonin-norepinephrine reuptake inhibitor (N = 424) we show that responders, but not non-responders, display an increase of GPR56 mRNA in the blood. In a small group of subjects we also show that GPR56 is downregulated in the PFC of individuals with depression that died by suicide. In mice, we show that chronic stress-induced Gpr56 downregulation in the blood and prefrontal cortex (PFC), which is accompanied by depression-like behavior, and can be reversed by antidepressant treatment. Gpr56 knockdown in mouse PFC is associated with depressive-like behaviors, executive dysfunction and poor response to antidepressant treatment. GPR56 peptide agonists have antidepressant-like effects and upregulated AKT/GSK3/EIF4 pathways. Our findings uncover a potential role of GPR56 in antidepressant response.

Identifiants

pubmed: 32242018
doi: 10.1038/s41467-020-15423-5
pii: 10.1038/s41467-020-15423-5
pmc: PMC7118175
doi:

Substances chimiques

ADGRG1 protein, human 0
Antidepressive Agents 0
GPR56 protein, mouse 0
Receptors, G-Protein-Coupled 0
Serotonin Uptake Inhibitors 0
Glycogen Synthase Kinase 3 EC 2.7.11.26

Banques de données

ClinicalTrials.gov
['NCT00635219', 'NCT00599911', 'NCT01140906', 'NCT02209142']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1635

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM120110
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS103946
Pays : United States
Organisme : CIHR
ID : FDN148374
Pays : Canada
Organisme : CIHR
ID : EGM141899
Pays : Canada

Références

Waraich, P., Goldner, E. M., Somers, J. M. & Hsu, L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can. J. Psychiatry 49, 124–138 (2004).
doi: 10.1177/070674370404900208
WHO. Depression and Other Common Mental Disorders: Global Health Estimates (2017).
Kennedy, S. H. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can. J. Psychiatry 61, 540–560 (2016).
doi: 10.1177/0706743716659417
Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917 (2006).
doi: 10.1176/ajp.2006.163.11.1905
Apazoglou, K. et al. Antidepressive effects of targeting ELK-1 signal transduction. Nat. Med. 24, 591–597 (2018).
doi: 10.1038/s41591-018-0011-0
McIntosh, A. L., Gormley, S., Tozzi, L., Frodl, T. & Harkin, A. Recent advances in translational magnetic resonance imaging in animal models of stress and depression. Front. Cell Neurosci. 11, 150 (2017).
doi: 10.3389/fncel.2017.00150
Suzuki, G. et al. Stress and electroconvulsive seizure differentially alter GPR56 expression in the adult rat brain. Brain Res. 1183, 21–31 (2007).
doi: 10.1016/j.brainres.2007.09.020
Svenningsson, P. et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl Acad. Sci. USA 99, 3182–3187 (2002).
doi: 10.1073/pnas.052712799
Wagner, S. et al. Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with major depressive disorder. PLoS ONE 13, e0194574 (2018).
doi: 10.1371/journal.pone.0194574
El Khoury, M. A., Gorgievski, V., Moutsimilli, L., Giros, B. & Tzavara, E. T. Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 36–50 (2012).
doi: 10.1016/j.pnpbp.2011.12.005
Stoveken, H. M., Hajduczok, A. G., Xu, L. & Tall, G. G. Adhesion G protein-coupled receptors are activated by exposure of a cryptic tethered agonist. Proc. Natl Acad. Sci. USA 112, 6194–6199 (2015).
doi: 10.1073/pnas.1421785112
Stoveken, H. M., Larsen, S. D., Smrcka, A. V. & Tall, G. G. Gedunin- and Khivorin-derivatives are small-molecule partial agonists for adhesion G protein-coupled receptors GPR56/ADGRG1 and GPR114/ADGRG5. Mol. Pharm. 93, 477–488 (2018).
doi: 10.1124/mol.117.111476
Gupta, M. et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol. Psychiatry 21, 1717–1725 (2016).
doi: 10.1038/mp.2016.6
Qi, X. R. et al. Abnormal retinoid and TrkB signaling in the prefrontal cortex in mood disorders. Cereb. Cortex 25, 75–83 (2015).
doi: 10.1093/cercor/bht203
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Zanos, P. & Gould, T. D. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry 23, 801–811 (2018).
doi: 10.1038/mp.2017.255
Beaulieu, J. M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psychiatry Neurosci. 37, 7–16 (2012).
doi: 10.1503/jpn.110011
Gould, T. D. & Manji, H. K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223–1237 (2005).
doi: 10.1038/sj.npp.1300731
Aguilar-Valles, A. et al. Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. Nat. Commun. 9, 2459 (2018).
doi: 10.1038/s41467-018-04883-5
Bae, B. I. et al. Evolutionarily dynamic alternative splicing of GPR56 regulates regional cerebral cortical patterning. Science 343, 764–768 (2014).
doi: 10.1126/science.1244392
Bai, Y., Du, L., Shen, L., Zhang, Y. & Zhang, L. GPR56 is highly expressed in neural stem cells but downregulated during differentiation. Neuroreport 20, 918–922 (2009).
doi: 10.1097/WNR.0b013e32832c92d7
Giera, S. et al. The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development. Nat. Commun. 6, 6121 (2015).
doi: 10.1038/ncomms7121
Giera, S. et al. Microglial transglutaminase-2 drives myelination and myelin repair via GPR56/ADGRG1 in oligodendrocyte precursor cells. Elife 7, e33385 (2018).
Peng, Y. M. et al. Specific expression of GPR56 by human cytotoxic lymphocytes. J. Leukoc. Biol. 90, 735–740 (2011).
doi: 10.1189/jlb.0211092
Hamann, J. et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharm. Rev. 67, 338–367 (2015).
doi: 10.1124/pr.114.009647
Della Chiesa, M. et al. GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues. Int. Immunol. 22, 91–100 (2010).
doi: 10.1093/intimm/dxp116
Luo, R. et al. G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. Proc. Natl Acad. Sci. USA 108, 12925–12930 (2011).
doi: 10.1073/pnas.1104821108
Chiang, N. Y. et al. Heparin interacts with the adhesion GPCR GPR56, reduces receptor shedding, and promotes cell adhesion and motility. J. Cell Sci. 129, 2156–2169 (2016).
doi: 10.1242/jcs.174458
Habib, N. et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955–958 (2017).
doi: 10.1038/nmeth.4407
Mamdani, F. et al. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl. Psychiatry 1, e13 (2011).
doi: 10.1038/tp.2011.12
Consoloni, J. L. et al. Serotonin transporter gene expression predicts the worsening of suicidal ideation and suicide attempts along a long-term follow-up of a major depressive episode. Eur. Neuropsychopharmacol. 28, 401–414 (2018).
doi: 10.1016/j.euroneuro.2017.12.015
Belzeaux, R. et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry 2, e185 (2012).
doi: 10.1038/tp.2012.112
Farley, S., Apazoglou, K., Witkin, J. M., Giros, B. & Tzavara, E. T. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J. Neuropsychopharmacol. 13, 1207–1218 (2010).
doi: 10.1017/S1461145709991076
Dournes, C., Beeske, S., Belzung, C. & Griebel, G. Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 213–220 (2013).
doi: 10.1016/j.pnpbp.2012.07.019
Crozatier, C. et al. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 144, 1470–1476 (2007).
doi: 10.1016/j.neuroscience.2006.11.030
Birrell, J. M. & Brown, V. J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320–4324 (2000).
doi: 10.1523/JNEUROSCI.20-11-04320.2000
Paxinos, G. & Franklin, K. B. J. The Mouse Brain in Stereotaxic Coordinates, 2nd edn. (Academic Press, 2001).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
doi: 10.1093/nar/gkv007
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289–300 (1995).
Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).
doi: 10.1371/journal.pone.0013984
Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116–5121 (2001).
doi: 10.1073/pnas.091062498

Auteurs

Raoul Belzeaux (R)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.
Aix-Marseille Univ, AP-HM, CNRS, INT, Inst Neurosci Timone, Hôpital Sainte Marguerite, Pôle de psychiatrie, Marseille, France.
Fondation FondaMental, Créteil, France.

Victor Gorgievski (V)

CNRS (Integrative Neuroscience and Cognition Center, UMR 8002), Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Laura M Fiori (LM)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Juan Pablo Lopez (JP)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Julien Grenier (J)

INSERM UMR-S 1124 ERL 3649, Université Paris Descartes, Paris, France.

Rixing Lin (R)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Corina Nagy (C)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

El Chérif Ibrahim (EC)

Aix-Marseille Univ, AP-HM, CNRS, INT, Inst Neurosci Timone, Hôpital Sainte Marguerite, Pôle de psychiatrie, Marseille, France.
Fondation FondaMental, Créteil, France.

Eduardo Gascon (E)

Aix-Marseille Univ, AP-HM, CNRS, INT, Inst Neurosci Timone, Hôpital Sainte Marguerite, Pôle de psychiatrie, Marseille, France.

Philippe Courtet (P)

Fondation FondaMental, Créteil, France.
Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France.

Stéphane Richard-Devantoy (S)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Marcelo Berlim (M)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Eduardo Chachamovich (E)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Jean-François Théroux (JF)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Sylvie Dumas (S)

Oramacell, 75006, Paris, France.

Bruno Giros (B)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Susan Rotzinger (S)

Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.

Claudio N Soares (CN)

St Michael's Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide Studies, Toronto, ON, Canada.
Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.

Jane A Foster (JA)

Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.

Naguib Mechawar (N)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.

Gregory G Tall (GG)

Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.

Eleni T Tzavara (ET)

Fondation FondaMental, Créteil, France.
CNRS (Integrative Neuroscience and Cognition Center, UMR 8002), Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Sidney H Kennedy (SH)

Centre for Mental Health, Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, ON, Canada.
St Michael's Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide Studies, Toronto, ON, Canada.

Gustavo Turecki (G)

Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada. gustavo.turecki@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH